Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue: +3,749.2%
EPS: +549.1%
Free cash flow: +839.7%

Quarter to June 2026, against a year earlier

133.80 1.46 −1.08%

Follow PTGX

Alert me

Market cap: $8.8B
P/E: 111×
Fwd P/E: 31.2×
Dividend yield: —
F-score: 4/9
Altman Z: 61.55
Beneish M: −7.18
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Protagonist Therapeutics, Inc. 10-K filed Feb 21, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 21, 2025 · accepted 4:36 PM ET · Document on sec.gov · Filing index

Red flags

Receivables outpacing revenue Feb 21, 2025
Receivables grew 1550.0% while revenue grew 624.1% year over year

10-K filed Feb 21, 2025 · The filing · sec.gov